RESEARCH MONOGRAPH · KDC-MN-107

Rhodiola Rosea

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

69/100

One of the more honest adaptogens in the herbal category. Salidroside and rosavin chemistry is real

Rhodiola rosea is the adaptogen that has the cleanest active-compound story among the herbal options. Salidroside (the tyrosol glycoside) and the rosavins are reasonably well-characterized, the standardization in Europe is decent (typically 3% rosavins and 1% salidroside), and the human trial base is small but not absent. Soviet and Scandinavian research traditions worked on this for decades before it became a Western nootropic.

The Olsson 2009 Swedish trial in burnout-related fatigue showed real effects on attention and stress measures. The Spasov 1999 Russian trial in medical students during exams (acute mental performance under stress) showed measurable improvements. These arent enormous trials but the consistency across studies of acute mental performance under fatigue or stress is decent.

Mechanistically the picture is multi-target. Salidroside has been shown in cell models to affect monoamine oxidase activity, HPA axis tone, AMPK signaling, and neurogenesis-related transcription. The hypothesis is that the molecule acts as a mild eustressor, recruiting endogenous stress-resistance pathways in a hormetic way. That hand-wavy framework gets used for most adaptogens but rhodiola actually has plausible biochemical correlates.

What we like: real active compounds with isolated identities (not just extract magic), consistent acute-stress/cognitive endpoint signals in small trials, good European GMP standardization. As far as herbal adaptogens go, this is among the more defensible.

What we dont like is the variability in commercial extracts. Anything not standardized to specified rosavins and salidroside content is essentially gambling on what you're getting. Wild-harvested Russian and Siberian material has been overexploited and quality is uneven. Cultivated material from Northern Europe is often more reliable.

Sourcing: look for extracts standardized to 3% rosavins and 1% salidroside (the classic Russian SHR-5 ratio used in most of the published trials), from suppliers with COA data. Pure salidroside is also available as a research compound at 98%+ HPLC purity for those who want to isolate one variable.

Honestly we think rhodiola holds up reasonably well in the adaptogen category. Not a miracle, real chemistry, real but modest acute effects in stress and fatigue contexts. The decades of Eastern European use mean the long-term safety profile is fairly well-understood for an herbal.

Evidence: 60
Mechanism: 60
Reliability: 62
Safety: 85
Sourcing: 70
Value: 75
Signal: 68
Staying power: 70

Plain-language summary Intrigue 60 / 100

Rhodiola rosea is an adaptogenic root from Arctic regions. The compound class rhodiosides (rhodiolosides) and rosavins are believed to mediate the anti-fatigue and stress-resistance effects. Used widely in Russia and Scandinavia for over 50 years. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Adaptogenic root extract

A root extract from the arctic adaptogen Rhodiola rosea standardized to rosavins and salidroside, with documented anti-fatigue and stress-tolerance effects.

Abstract

Rhodiola rosea is a perennial root used in traditional Russian, Scandinavian, and Chinese medicine for fatigue, stress, and cognitive enhancement. The active constituents include rosavins (rosavin, rosin, rosarin) and salidroside (a phenolic glycoside), with most clinical preparations standardized to 3 percent rosavins and 1 percent salidroside (the SHR-5 extract used in Russian and Swedish trials). Multiple randomized trials have demonstrated improvements in fatigue measures, mental performance under stress, and depressive symptoms. Mechanism includes modulation of HPA axis cortisol response, monoamine oxidase inhibition (modest), and antioxidant activity. Reported research dose ranges in the literature are typically 200 to 600 mg of the standardized extract. The compound is sold widely as a dietary supplement.

Mechanism of action

HPA axis cortisol response modulation; modest MAO inhibition; antioxidant. Multiple bioactive constituents.

Reported research dose ranges

200 to 600 mg of standardized extract (reported research dose ranges in the literature).

References

Hung SK, et al. The effectiveness and efficacy of Rhodiola rosea L.: a systematic review of randomized clinical trials. Phytomedicine 2011.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-107

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Rhodiola Rosea

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs